For example, from this paper: Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing:
| Gene |
Peptide |
MHC allele |
IC50 (mut) |
IC50 (WT) |
Mutation position |
Immunogenicity prediction |
| Dpagt1 |
SIIVFNL[V/L] |
H-2Kb |
8 |
34 |
Anchor (P8) |
− |
| Reps1 |
AQL[P/A]NDVVL |
H-2Db |
9 |
100 |
Solvent (P4) |
+ |
| Adpgk |
ASMTN[R/M]ELM |
H-2Db |
2 |
3 |
Solvent (P6) |
+ |
| Cpne1 |
SSP[D/Y]SLHYL |
H-2Db |
211 |
685 |
Solvent (P4) |
− |
| Irgq |
AALLNSA[G/V]L |
H-2Db |
3 |
52 |
Solvent (P8) |
− |
| Aatf |
MAPIDHT[A/T]M |
H-2Db |
30 |
102 |
Solvent (P8) |
− |
| Med12 |
DPSSSVLFE[D/Y] |
H-2Kb |
38,300 |
39,411 |
No structure |
− |
and looks like these pentamers are sold by Proimmune: https://www.proimmune.com/list-of-catalog-pentamers/
We can also try to get these peptides synthesized and pulse a non-MC38 cell line with them to see if they make it susceptible to our TCRs.